L-701,324
L-701,324 Basic information
- Product Name:
- L-701,324
- Synonyms:
-
- 7-CHLORO-4-HYDROXY-3-(3-PHENOXY)PHENYL-2(1H)-QUINOLINONE
- 7-CHLORO-4-HYDROXY-3-(3-PHENOXY )PHENYLQUINOLIN-2[1H]-ONE
- 7-Chloro-4-hydroxy-3-(3-phenoxy)phenyl-2(H)-quinolinone
- L-701,304
- 7-chloro-1-(4-hydroxy-3-phenoxyphenyl)quinolin-2(1H)-one
- CS-2045
- 7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-1H-quinolin-2-one
- L-701
- CAS:
- 142326-59-8
- MF:
- C21H14ClNO3
- MW:
- 363.79
- Product Categories:
-
- Inhibitors
- Mol File:
- 142326-59-8.mol
L-701,324 Chemical Properties
- Melting point:
- 308 °C
- Boiling point:
- 584.7±50.0 °C(Predicted)
- Density
- 1.389±0.06 g/cm3(Predicted)
- storage temp.
- Sealed in dry,Room Temperature
- solubility
- DMSO: soluble36.4mg/mL
- form
- solid
- pka
- 4.50±1.00(Predicted)
- color
- White to off-white
MSDS
- Language:English Provider:SigmaAldrich
L-701,324 Usage And Synthesis
Uses
L-701,324 is a potential anticonvulsant with high selectivity and affinity for the NMDA receptor glycine site. NMDA receptors are expressed by small-cell lung cancer and are potential targets for effective treatment.
Definition
ChEBI: 7-chloro-4-hydroxy-3-(3-phenoxyphenyl)-1H-quinolin-2-one is a member of quinolines.
Biological Activity
An orally active and long acting anticonvulsant with high affinity and selectivity for the glycine site on the NMDA receptor.
in vivo
L-701324 (5-10 mg/kg; i.p.; once) exhibits antidepressant-like potential in the forced swim test (FST) and tail suspension test (TST) without affecting the locomotor activity of mice[1].
L-701324 (5-10 mg/kg; i.p.; daily, for 2 weeks) produces strong antidepressant-like effects in the chronic unpredictable mild stress (CUMS) model of depression and prevents the CUMS-induced decreases in eurogenesis and the BDNF signaling cascade in the hippocampus[1].
L-701324 (2.5-5 mg/kg; p.o.; once) inhibits NMDA receptor activity via a blockade of the NMDA/glycine-sensitive site at the NMDA receptor is accompanied by a reduction of anxiety-like behavior in both non-conditioned and conditioned conflict behavior situations[2].
| Animal Model: | Male C57BL/6 J mice in the chronic unpredictable mild stress (CUMS) (7 weeks of age) [1] |
| Dosage: | 5 and 10 mg/kg |
| Administration: | Intraperitoneal injection; daily, for 2 weeks |
| Result: | Reduced the immobility of C57BL/6 J mice. Increased the expression of BDNF, pTrkB and pCREB in the hippocampus. |
| Animal Model: | Male C57BL/6 J mice in the forced swim test (FST) and tail suspension test (TST) (7 weeks of age)[1] |
| Dosage: | 5 and 10 mg/kg |
| Administration: | Intraperitoneal injection; once |
| Result: | Reduced the immobility of C57BL/6 J mice in the FST and TST. |
| Animal Model: | Male Sprague-Dawley rats (280-300 g)[2] |
| Dosage: | 2.5 and 5 mg/kg |
| Administration: | Oral administration; once |
| Result: | Increased in the percentage of time spent in the open arm in a dose-dependent. Increased punished responding in the Vogel's conflict test in a dose-dependent fashion. |
IC 50
NMDA Receptor
storage
Store at RT
L-701,324Supplier
- Tel
- sales@boylechem.com
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- 0757-86329057 18934348241
- sales4.gd@hwrkchemical.com
- Tel
- 021-54306202 13764082696
- info@hanhongsci.com
- Tel
- 021-58950125
- info@chemexpress.com